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Abstract:  
Resistance to platinum and taxane based chemotherapy remains a major clinical impediment to 
effective management of epithelial ovarian cancer (EOC). To gain insights into resistance 
mechanisms, we compared gene and confirmed expression patterns of novel EOC cell lines 
selected for paclitaxel and carboplatin resistance. Here we report that resistance can be conferred 
by downregulation of the polo-like kinase Plk2. Mechanistic investigations revealed that 
downregulation occurred at the level of transcription via associated DNA methylation of the 
CpG island in the Plk2 gene promoter in cell lines, primary tumors, and patient sera. RNAi-
mediated knockdown and ectopic overexpression established a critical functional role for Plk2 in 
determining apoptotic sensitivity to paclitaxel and carboplatin. In drug resistant human EOC cell 
lines, Plk2 promoter methylation varied with the degree of drug resistance and transcriptional 
silencing of the promoter. RNAi-dependent knockdown of Plk2 abrogated G2-M cell cycle 
blockade by paclitaxel, conferring resistance to both paclitaxel and platinum. Conversely, ectopic 
expression of Plk2 restored sensitivity to G2-M cell cycle blockade and cytotoxicity triggered by 
paclitaxel. In clinical cases, DNA methylation of the Plk2 CpG island in tumor tissue was 
associated with a higher risk of relapse in patients treated post-operatively with carboplatin and 
paclitaxel (p= 0.003). This trend was also reflected in analysis of matched serum samples. Taken 
together, our results implicate Plk2 as a clinically important determinant of chemosensitivity, in 
support of the candidacy of Plk2 as a theranostic marker to inform EOC management. 
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Introduction 
The Polo-like kinases (Plks) are a family of serine-threonine kinases invovled in cell cycle 
regulation and cellular response to stresses e.g. DNA damage. Plk1 is the best characterised 
and positively regulates progression through G2 (1). Polo-like kinase 2/Snk (Plk2) and 
Polo-like kinase 3 Plk3/Fnk/Prk (Plk3) were identified as immediate-early transcripts in 
mouse fibroblasts (2 - 4), whilst Plk4 (SAK) functions in centriole biogenesis (5 - 9).  Plk1 is 
over-expressed in various cancers supporting treatment strategies designed to target it 
(10, 11). Plk2 has a role in development and is required for centriole duplication (12, 13), 
although Plk2 -/- mice are viable (14). Plk2 induces apoptosis in Burkitt’s lymphoma (BL) 
cells (15) and expression is directly induced by wild-type p53 (16). Under normal 
physiological conditions, Plk2 protein is subject to proteosomal degradation via the 
ubiquitin ligase hVPS18 (17). Methylation-dependent transcriptional silencing of Plk2 is 
common in BL (15). Transcriptional silencing of many genes is described for EOC (18).  
EOC is often a chronic disease, characterized by long-term responsiveness to 
chemotherapy. Cisplatin and carboplatin are key agents in EOC management and cancers 
may retain sensitivity to these drugs for prolonged periods and sometimes, even after 
clinical relapse. Paclitaxel (Taxol®) and docetaxel (Taxotere®) are frequently used in 
combination with platinum for treating EOC. There is emerging evidence that epigenetic 
changes contribute significantly to acquired chemotherapy resistance (19 -21). We show 
herein that Plk2 is a determinant of sensitivity to paclitaxel and platinum. 
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Materials and Methods 
Drugs used: 
Carboplatin, cisplatin, paclitaxel, 5’-Aza-cytidine and Trichostatin A were obtained from 
Sigma Aldrich, Poole, UK). 
 
Cell lines and plasmids 
Primary normal ovarian surface epithelial cells (OSE) were prepared as described (22). 
A2780 cells were obtained from European Collection of Cell Cultures (ECACC, Salisbury, 
UK). SKOV-3 cells were obtained from ATCC (LGC Promochem, Teddington, UK). Cell lines 
were authenticated at source by STR profiling, morphology (ATCC) and DNA profiling 
(ECACC). Sub-lines of A2780 and SKOV-3 ovarian carcinoma cell lines with acquired 
resistance to paclitaxel and carboplatin (SKOV-3TaxR and SKOV-3CR, respectively) were 
derived by sequential, pulsed exposure to increasing concentrations of drug. Maintenance 
doses for the drug resistant cell lines were generally sub-IC50 doses and representative of 
clinically achievable levels.  
 
Transfection (Knock-in) and Silencing (Knock-down) of Plk2 
Stable knock-down was achieved using plasmid-based RNAi. Sequences (from Ambion) 
were ligated into pSilencer. A2780 cells were transfected with pSilencer plasmids using 
Lipofectamine (Invitrogen, Paisley, UK) and selected in hygromycin B. Cells were then 
challenged with paclitaxel and subjected to flow cytometry. The plasmid for ectopic 
expression of Plk2 was described previously (15). For transient, RNAi-mediated 
knockdown of Plk2, we used reagents provided by Smartpool (Dharmacon; 
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ThermoScientific, UK) according to the manufacturer’s protocol. Following 72h of silencing, 
SKOV-3 cells were sub-cultured into T252 tissue culture flasks at approximately 30-50% 
confluence and exposed to paclitaxel (10nM) or carboplatin (100μM) (both used at 
approximately twice the IC50 dose) for a period of 48h, then harvested and subjected to the 
annexin assay.  
 
Clinical Samples 
Samples of EOC were obtained from the Tissue Bank of the Charité Hospital, Berlin, 
Germany. Tissue obtained at initial debulking surgery and at first relapse (obtained with 
informed consent and local ethical committee approval) were collected as snap-frozen 
biopsies at surgery. Serum was collected at the time of diagnosis and relapse and stored at -
80 o C. Genomic DNA was obtained from tissues using proteinase K/ phenol and from serum 
using the Qiagen system. Cases were predominantly serous adenocarcinomas (n= 43), but 
also included endometrioid carcinomas (n= 5), mucinous (n=1), clear cell (n=1), mixed 
histology (n=2) and 2 unclassified cases (Table 2). Post-operative chemotherapy comprised 
carboplatin and paclitaxel for all patients, given on either a 21 day (q21) or 7 day (q7) 
schedule. In some cases Gemcitabine was added. Response was assessed by standard 
criteria including clinical examination, serum CA125 and computerized tomographic (CT) 
imaging. 
 
mRNA analysis 
Analysis of Plk2 expression by RT-PCR and qPCR was as described previously (15). 
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Methylation analysis 
Genomic DNA was purified from cell pellets by proteinase K digestion and from serum 
using a commercially available system (Qiagen). For methylation analysis, genomic DNA 
(1μg) was modified by sodium bisulphite as described previously (15). The location of 
primers for bisulphite sequencing and MSP is shown in Supplementary Material, Figure 1. 
qMSP of the Plk2 CpG island was carried out using primer pair 4. PCR was performed in an 
ABI PRISM 7700 Sequence Detection System (Applied Biosystems) using SyBRGreen 
(Qiagen).  
 
Western blotting 
Cell pellets were prepared from attached and floating cell populations, then subjected to 
osmotic rupture in hypotonic detergent based buffer (1mM PMSF, NaVO4, aprotinin and 
leupeptin as protease inhibitors, 150mM NaCl, in 50mM Tris buffer, 0.2% SDS, 1% NP-40, 
pH 7.5) and 40-50μg of protein/sample electrophoresed on SDS-PAGE gels. Membranes 
were incubated overnight at 40C with primary antibody- Plk2 antibody (sc-25421, H-90 
rabbit polyclonal antibody, Insight Biotechnology, London, UK) or Plk1,3 and 4 (AbCam, 
Cambridge, UK). In some experiments, the anti-Plk2 antibody used was as described 
previously (13, 15). Following the probing of each membrane with the primary antibody of 
choice, the membrane was stripped and re-probed using a GAPDH, PCNA or actin antibody 
as loading control. Antibodies against Plk1, Plk3 and Plk4 were from AbCam. 
 
Cytotoxicity assays 
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A2780 and SKOV-3 parental and resistant cells for cytotoxicity testing were seeded into 96-
well plates at a density of 3-4 x 104 cells/ml to allow approximately 3-doublings 
(approximately 10-20-fold increase in control cell number) for the duration of the drug 
exposure. Cells were allowed to attach and equilibrate for 24h, then treated with various 
concentrations of drug over 2-3 log orders of concentration. Results were not materially 
affected by initial plating densities. Drugs were diluted in tissue culture medium containing 
10% FCS. Control cell wells were treated with drug-free tissue culture medium. Drug-
treated cells were then returned to the incubator for a period of 72h. Cell viability was 
determined by addition of 0.1mg MTT (thiazoyl blue tetrazolium bromide) to each well for 
4h at 37o C. Wells were aspirated to remove the medium, the resulting formazan crystals 
solubilized in 200μl DMSO and the absorbance read at 570nM. The absorbance of the 
formazan product obtained for drug-treated cells was calculated as a fraction of that for the 
untreated control wells. Growth curves were constructed using PRISM software and results 
expressed as IC50 values i.e. dose of drug causing a 50% reduction in cell viability. 
 
Annexin V assay for assessment of apoptosis: 
The effect of drugs on cell cycle distribution was assessed by flow cytometry as described 
previously (15). Cell death was assessed by measurement of apoptosis using Annexin V. 
Briefly, cells were seeded into tissue culture flasks to give a density approximately 30-50% 
confluence (for SKOV-3 and A2780 cell lines this corresponded to 4 x 105 cells / T25flask), 
allowed to attach for 2-3 hours and then treated for 48h with the appropriate compound at 
various concentrations. In our hands, initial plating densities between 20 and 50% did not 
significantly affect apoptosis induction in this assay. An Annexin V-FITC conjugated 
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apoptosis detection kit incorporating PI was used according to the manufacturer’s protocol 
(Oncogene; supplied by CN Biosciences, Beeston, UK). Harvesting of cells included 
collection of attached cells (following trypsinization) and floating cells. Samples were 
analysed by flow cytometry, using the FL1 (FITC) and FL3 (PI) laser lines and each sample 
was assessed using a collection of 10,000 events. All analyses were carried out in triplicate. 
 
Statistical analysis 
 
Statistical analysis was carried out using SPSS (version 14) and MiniTab programs. Tissue 
and serum methylation results were assessed in the groups of responders and non-
responders in terms of the utility of DNA methylation as a potential marker of chemo-
responsiveness. 
 
 
 
Results 
 
Ovarian carcinoma cell lines with primary resistance to paclitaxel show cross-
resistance to platinum and vice versa 
We derived, de novo, a series of novel A2780 EOC cell lines with increasing degrees of 
acquired resistance to paclitaxel (supplementary Table1). Calculating the relative 
resistance (as a Resistance Factor), using the ratio of IC50 resistant variant / IC50 of parental 
cell line (1.5 nM) we derived the nomenclature for the A2780TaxR panel of cell lines: hence 
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A2780TaxR354 is 354-fold resistant to paclitaxel, etc. We also developed independent 
SKOV-3 cell lines with primary resistance to paclitaxel and carboplatin  SKOV-3TaxR was 
52 -fold resistant, compared to the parental SKOV-3 cell line (IC50 = 5.7 nM) and SKOV-3CR 
cell lines 3-fold resistant to carboplatin (IC50= 298.0 μM) and 2-fold resistant to cisplatin 
(IC50= 21.7μM) (supplementary Table1). We tested whether cell lines with acquired 
resistance to paclitaxel were cross-resistant to platinum compounds and vice versa. 
Paclitaxel-resistant cell lines were challenged with carboplatin or cisplatin and cytotoxicity 
evaluated. In each cell line in our series, paclitaxel-resistant cell lines showed decreased 
sensitivity to cisplatin and carboplatin (Figure 1, supplementary Table1).  Conversely, 
SKOV-3CR cells showed decreased sensitivity to paclitaxel (Figure1, supplementary 
Table1). 
 
Drug resistance is associated with loss of G2M checkpoint 
Using annexin V staining and flow cytometry, we asked whether resistance to paclitaxel 
was associated with changes in drug-induced apoptosis and/or cell cycle distribution. In 
A2780TaxR354 paclitaxel-resistant cell lines, there was greatly reduced apoptosis on 
exposure to paclitaxel relative to parental cells (Figure 2A). The apoptotic effects of drug 
treatment could be seen by the emergence of annexin V positive (quadrants top right and 
bottom right) and PI positive populations (emergence towards top left/right quadrants). 
Summation of the apoptotic quadrants revealed approximately 49% and 25% cell death for 
A2780 parent and A2780TaxR354 cells, respectively following treatment with paclitaxel. 
Likewise, following treatment with cisplatin a clear reduction in the extent of cell death is 
also seen comparing A2780 parent and A2780TaxR354 resistant cells. Next, we analyzed 
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perturbations in cell cycle following drug exposure. Following 24h paclitaxel exposure 
A2780 parent cells, sub-G1 (apoptotic) and G2M arrested populations were clearly 
increased  (Figure 2B), but in paclitaxel-resistant A2780TaxR354 cells, there was no 
increase in the sub-G1 population. Furthermore, the G2M population was greatly reduced 
in A2780TaxR354 cells relative to A2780 parental cells (Figure 2B). Together, these results 
imply that acquired resistance to paclitaxel involves loss of G2M cell cycle checkpoint 
function and abrogation of apoptosis. In SKOV-3 parent cells, paclitaxel exposure resulted 
in clear increase in the apoptotic cell population which was completely absent in SKOV-
3TaxR cells (Figure 2C). In carboplatin resistant SKOV-3CR cells, there was reduced 
apoptosis on exposure to paclitaxel (Figure 2C). 
 
Transcriptional silencing of Plk2 in cell lines with acquired drug resistance 
Next, we analysed the expression and regulation of Plk2. Plk2 mRNA was abundantly 
expressed in normal ovarian surface epithelium (OSE) and in the parent A2780 and SKOV-3 
lines (Figure 3A and 3B). There was, however, down-regulation of Plk2 mRNA in 
A2780TaxR354, SKOV-3TaxR (paclitaxel-resistant) and SKOV-3CR (carboplatin resistant) 
cells relative to the respective parent lines (Figure 3A and 3B). Western blot analysis 
confirmed reduced levels of Plk2 protein in paclitaxel resistant A2780 and SKOV-3 cell 
lines (Figure 3C).  In contrast, there was no change in expression of Plk1 or Plk3 between 
parent and paclitaxel-resistant A2780 and SKOV-3 cell lines (Figure 3D). Plk4 levels were 
higher in A2780 TaxR354 cells but not in SKOV-3TaxR. To investigate whether down-
regulation of Plk2 mRNA is associated with methylation changes, we performed bisulphite 
sequencing of the Plk2 CpG island, The CpG island was unmethylated in OSE, in the parent 
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A2780 and SKOV-3 EOC cell lines and in other EOC cell lines. However, in A2780TaxR354 
and SKOV-3TaxR cells, there was acquisition of methylation within a defined region of the 
CpG island (Figure 4A). We tested whether demethylating agents reactivate expression of 
Plk2 mRNA and observed an increase in Plk2 mRNA after exposure to 5’-Aza-cytidine (Aza-
C) (Figure 4B), consistent with methylation-dependent silencing. Using both conventional 
and quantitative MSP (qMSP), we confirmed that methylation was detectable in the 
paclitaxel-resistant derivatives A2780TaxR354 and SKOV-3TaxR, but not in the respective 
parent cell lines (Figure 4C and 4D). 
 
Methylation and expression of Plk2 vary quantitatively with drug resistance 
We analysed expression and methylation of Plk2. in our panel of paclitaxel resistant 
variants of A2780. Bisulphite sequencing showed a progressive, quantitative increase in 
methylation with increasing drug resistance (Figure 5A). qMSP analysis confirmed that 
methylation increased with increasing paclitaxel resistance (Figure 5B). Expression of Plk2 
mRNA (Figure 5C) and protein (Figure 5D) decreased with increasing paclitaxel resistance, 
consistent with changes in CpG methylation.  
 
Paclitaxel resistance correlates with epigenetic status of the Plk2 CpG island 
We next tested the stability of the drug resistant phenotype. Clones of the A2780 paclitaxel-
resistant cell line panel with increasing levels of primary resistance to paclitaxel, were 
transferred to drug-free medium and grown continuously in the absence of paclitaxel. After 
6 weeks growth in drug-free medium, A2780TaxR354 cells grown in the absence of 
paclitaxel (-) had substantially reverted to a paclitaxel sensitive phenotype (Figure 6A). In 
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A2780TaxR615 (-) cells, there was a clear, but less complete, restoration of the paclitaxel-
induced G2M block (Figure 6A). Plk2 expression in A2780TaxR354 (-) had returned to 
almost 75% of the level of parental cells and that of A2780TaxR615 (-) to approximately 
33% of parent A2780 cells (Figure 6B, light grey panels) but remained suppressed in cells 
exposed to maintenance paclitaxel (dark grey panels). MSP analysis of the Plk2 CpG island 
showed a decrease in methylation with recovery of Plk2 expression (Figure 6C) and this 
was confirmed by bisulphite sequencing of the Plk2 CpG island (Supplementary Material, 
Figure 2). 
 
Plk2 expression modulates cytotoxicity of carboplatin and paclitaxel 
We used plasmid-mediated inhibitory RNA (RNAi) to stably down-regulate Plk2 in the drug 
sensitive A2780 parent cell line. Knock-down was confirmed by RT-PCR (“KD” in Figure 
7A). Clonal cell lines with “knocked-down” expression of Plk2 (A2780KD) were challenged 
with a cytotoxic concentration of paclitaxel (Figure 7B). G2M block and increase in the sub-
G1 population were greatly reduced in the knocked-down cells (Figure 7B). To exclude so-
called “off-target” effects, A2780 cell lines with knocked-down Plk2 (A2780KD) were re-
transfected with a Plk2 expression plasmid (A2780KD + KI). The effect of Plk2 re-
expression was increased paclitaxel-induced G2M blocked and sub-G1 populations, relative 
to the A2780KD cells (Figure 7B). Next, we ectopically expressed Plk2 in A2780TaxR354 
cells which have undetectable levels of endogenous Plk2. Flow cytometry revealed that in 
A2780TaxR354 KI cell lines engineered to ectopically express Plk2, there was restoration of 
the paclitaxel-dependent G2M checkpoint which was lost in the A2780TaxR354 cells (Figure 
7C). Finally, we used transient transfection of Plk2 siRNA to silence expression in SKOV-3 
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parental cells. Western blotting confirmed down-regulation of Plk2 expression (Figure 7D). 
The silenced cells were exposed to paclitaxel and carboplatin for 48h. There was a 
reproducible reduction in apoptosis induced by both paclitaxel and carboplatin in cells 
silenced for Plk2 expression compared to control cells  (Figure 7E). 
 
Plk2 is a candidate predictor of chemotherapy resistance in EOC 
We used quantitative MSP (qMSP) to analyse methylation in the Plk2 CpG island in a test 
series of 54 cases of EOC, treated in a single centre with post-operative carboplatin/ 
paclitaxel chemotherapy. 34 cases had relapsed clinically at the time of censor (as 
evidenced by rising serum CA125 levels and/or CT evidence of progressive disease), 
whereas 20 cases remained disease-free at the time of censor. Full clinical details of the 
cases are given in supplementary Table 2. Methylation in tumour tissues in the Plk2 CpG 
island was detected, using qMSP, in 19/54 (31%) cases at diagnosis. Cases with 
methylation in tumour tissue at diagnosis were more likely to have relapsed at the time of 
censor than those with undetectable methylation in tumour tissue at diagnosis (p=0.0032, 
Fisher’s exact test). We also performed qMSP for Plk2 CpG methylation in serum (where 
available). 39/50 sera were concordant with the methylation status of their matched 
tumour tissue (Fisher’s exact test, p=0.00216). We asked whether the presence of 
methylated Plk2 DNA in serum was more common at relapse than at diagnosis. Paired sera 
at diagnosis and relapse were available for 32 cases. 23/32 sera were concordant with the 
matched tissue (p=0.011, Fisher’s exact test). The proportion of sera with detectable 
methylation was higher at relapse than at diagnosis but because of small sample numbers 
this did not reach statistical significance (0.47 vs 0.62, p=0.204). Although there was a clear 
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trend for shorter relapse-free survival in cases with detectable methylated DNA from the 
Plk2 CpG island, both in tumour tissue and serum, this did not reach statistical significance 
with the small numbers of cases available for study (p= 0.142 for tissue and 0.054 for 
serum). See Supplementary Material, Figure 3 for additional data and Kaplan-Meier 
survival curves. These data suggest that detection of methylated Plk2 DNA may have utility 
in prediction of clinical outcome in EOC. 
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Discussion 
We show that Plk2 is a determinant of cellular sensitivity to paclitaxel and carboplatin and 
via a mechanism of methylation-dependent transcriptional silencing, Plk2 is associated 
with drug resistance. Paclitaxel resistance in A2780 cell lines was associated with 
reduction or complete loss of the drug-induced G2M checkpoint and reduced apoptosis. 
Similarly, in paclitaxel or carboplatin resistant SKOV-3 cells, there was reduced apoptosis 
relative to drug-sensitive parental cells. Importantly, in A2780 and SKOV-3 cell lines with 
acquired resistance to paclitaxel, there was significantly reduced apoptosis when 
challenged with platinum compounds. Moreover, carboplatin-resistant SKOV-3 cells 
exhibited reduced apoptosis when exposed to paclitaxel.  
Plk2 has both G2M checkpoint (16) and pro-apoptotic (15) function(s), prompting us to ask 
whether changes in expression of Plk2 occur with acquisition of drug resistance. Plk2 
expression was reduced relative to parent cell lines in A2780 and SKOV-3 cell lines with 
acquired resistance to paclitaxel and also in a SKOV-3 cell line resistant to carboplatin. The 
specificity of these effects was emphasised by analysis of the related genes Plk1 and 
Plk3/Fnk/Prk in which there were no changes in expression with acquisition of resistance 
to paclitaxel. Three other lines of experimental evidence support an important role for Plk2 
as a determinant of drug sensitivity. First, ectopic expression of Plk2 in cells in which 
endogenous Plk2 was epigenetically down-regulated, substantially restored sensitivity to 
paclitaxel. Secondly, RNAi-mediated “knock-down” of Plk2 in drug sensitive A2780 and 
SKOV-3 parental cell lines conferred reduced sensitivity to paclitaxel and platinum 
compounds, accompanied by reduced G2M block and apoptosis, an effect reversible by re-
expression of Plk2. Thirdly, low to moderate degrees of paclitaxel resistance were 
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reversible when cells were allowed a drug-free “holiday”. In such cell lines, with reacquired 
drug sensitivity, expression of Plk2 increased with increasing drug sensitivity. Our results 
are compatible with studies showing that decreased sensitivity to paclitaxel is associated 
with compromised checkpoint function or spindle assembly (24-26). Our data are also 
consistent with micro-array analyses of platinum-resistant cell lines in which Plk2 is down-
regulated (21; 27). Together, these results afford further support for the candidacy of Plk2 
as a determinant of chemotherapy sensitivity and for a predominantly epigenetic basis for 
acquired drug resistance (28). Our data also imply that Plk2 expression and Plk2-
associated kinase activity may be required, at least in some cell types, for sensitivity to 
chemotherapy. This is supported by a recent study in chronic lymphocytic leukaemia in 
which failure of Plk2 upregulation was associated with chemotherapy resistance (29). 
 
Our hypothesis, that dynamic changes in the epigenetic status of Plk2 influence the drug 
sensitivity of cancer cells, is supported by various lines of evidence from other authors. For 
example, changes in DNA methylation within the CpG islands of specific genes are 
detectable very rapidly after exposure to cytotoxic agents (30). Also, increasing cisplatin 
resistance in vivo is associated with elevated expression of methyltransferases and 
quantitative changes in CpG island methylation (21). In vivo supportive evidence comes 
from studies of the DNA mismatch repair gene hMLH1. Inactivation of hMLH1 is associated 
with increased resistance to cisplatin in vitro. Analysis of methylated DNA in serum of 
individuals receiving platinum-based adjuvant chemotherapy for EOC revealed that 
methylation levels changed during chemotherapy and had utility in predicting clinical 
outcome (23). A profiling study of global changes in the methylome of drug sensitive and 
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resistant MCF-7 cells, supports a general model of acquired drug resistance in which 
opposing and ongoing hypo- and hypermethylation in multiple genes is a major mechanism 
driving the process of drug resistance (31). In initial clinical studies we show that cases of 
EOC with Plk2 methylation at diagnosis were at significantly increased risk of early clinical 
relapse with a less favourable response to post-operative chemotherapy than cases lacking 
methylation. Also, methylated Plk2 DNA in serum was more common at clinical relapse 
than at initial diagnosis. Our results imply that analysis of Plk2 methylation may have 
utility as a biomarker of both disease activity and of chemo-sensitivity in EOC. In the 
context of our results, Plk2 has been identified as a significantly down-regulated gene in 
chemotherapy-resistant primary ovarian carcinomas, affording independent validation of 
our hypothesis for it being a determinant of chemotherapy sensitivity and candidate 
biomarker in EOC (32).  An important feature of the taxane resistant cell line models we 
use in the current study is their cross-resistance with platinum agents. In support of this, 
previous reports in the literature cite decreased platinum sensitivity with cross resistance 
to chemotherapeutic agents such as taxanes in EOC cell lines (33). Clinically, a proportion 
of EOC patients show platinum-taxane non-cross resistance (34). Both our cell line panel 
data and our EOC patient cohort used in the present study are representative of platinum 
and taxane cross-resistance.  
We previously reported that Plk2 is subject to transcriptional down-regulation in B 
lymphomas and expression profiling has shown that Plk2 down-regulation is a predictor of 
poor clinical outcome in B lymphomas (35). Our data are in support of clinical trials of 
epigenetic therapies in EOC patients, and other cancer patients (36) and suggest that 
detection of methylated Plk2 DNA warrants independent evaluation in larger clinical series 
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as a candidate predictor of response of EOC patients to chemotherapy and as a serum 
biomarker of drug-resistant clinical relapse. 
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Figure legends 
 
Figure 1: A: Dose-response curves for A2780 cells with increasing levels of acquired 
paclitaxel resistance. B: Dose-response curves of A2780 cells with varying levels of 
paclitaxel resistance challenged with carboplatin. Cells were treated with varying 
concentrations of each drug as indicated and survival determined (see Methods). Data are 
mean +/- 1SD from multiple independent experiments (at least four). C: Dose-response 
curves for SKOV-3 cells with acquired resistance to paclitaxel or carboplatin, challenged 
with paclitaxel. D: Dose-response curves for SKOV-3 cells with acquired resistance to 
paclitaxel or carboplatin, challenged with carboplatin. Cell lines were treated with varying 
concentrations of each drug as indicated and survival determined as described in Methods. 
Data shown are mean +/- 1SD from multiple independent experiments (at least four). 
Figure 2:  
Paclitaxel resistance and cross-resistance to platinum is associated with reduced apoptosis 
and changes in cell cycle distribution on exposure to drugs. A: Annexin staining of parent 
A2780 and A2780 paclitaxel-resistant cells grown in the presence of the indicated 
concentrations of paclitaxel or cisplatin and then subjected to the annexin V (AV) assay 
with propidium iodide (PI) staining. The proportions of cells in each compartment are 
indicated. A representative analysis (mean and (SD) from 3 independent experiments) is 
shown. Bottom left = viable cells; bottom right = early apoptotic (annexin- FITC +ve); top 
right = PI and AV +ve cells mid/late phase apoptosis; top left = end stage 
apoptosis/necrotic PI +ve. A representative analysis (typical of three independent 
experiments) is shown, with mean and (SD) indicated. B: Parent A2780 cells and 
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A2780TaxR354 were exposed to paclitaxel then subjected to flow cytometry. C: SKOV-3 
parent cells, SKOV-3TaxR and SKOV-3CR were exposed to paclitaxel, then subjected to flow 
cytometry (data shown are representative of repeat experiments).   
 
Figure 3. 
A and B: RT-PCR and qPCR analysis of expression of Plk2 in EOC cell lines and primary, 
normal ovarian surface epithelial (OSE) cells. Upper panel (A) shows RT-PCR analysis of 
Plk2 and the control gene GAPDH. Mr is molecular weight markers. The lower panel (B) 
shows qPCR analysis of expression of Plk2 in the same samples. C: Western blot analysis of 
Plk2 expression in parental A2780 and SKOV-3 EOC cell lines and the paclitaxel-resistant 
derivatives A2780TaxR354 and SKOV-3TaxR. D: Western blot analysis of Plk1, Plk3 and Plk4 
expression in parent A2780 and SKOV3 cells and in A2780TaxR354 and SKOV-3TaxR. The 
anti-Plk2 antibody used for western blotting detects a doublet, the upper band of which is 
Plk2 (arrowed). PCNA is shown as a loading control. 
 
Figure 4 
A: Bisulphite sequence traces showing acquired CpG methylation in A2780TaxR354 cells. B: 
Cell lines were treated with 5-aza-cytidine (+A) or 5-aza-cytidine and Trichostatin A (+AT) 
and expression of Plk2 analysed by RT-PCR. C: MSP analysis of methylation in parent and 
paclitaxel-resistant EOC cell lines. Controls are CU (unmethylated DNA) and CM (methylated 
DNA). MSP reactions for unmethylated (U) and methylated (M) alleles are shown. D: qMSP 
analysis of the Plk2 CpG island in parent and paclitaxel-resistant EOC cell lines.  
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Figure 5 
A: Bisulphite sequence analysis of the Plk2 CpG island in A2780 parent cells and sub-lines 
with increasing resistance to paclitaxel. Methylation is quantified by the number of black 
squares: 0 - no black blocks; 1-25% - 1 black block; 25-50% - 2 black blocks; 50-75% - 3 
black blocks; 75-100% - 4 black blocks. B: qMSP analysis of the Plk2 CpG island in parent 
A2780 cells and sub-lines with increasing levels of paclitaxel resistance. C: qPCR analysis of 
Plk2 mRNA in A2780 cell lines with increasing paclitaxel resistance. Levels of Plk2 mRNA 
are indicated relative to A2780 parent cells. D: Western blot analysis of Plk2 expression in 
A2780 cell lines with increasing paclitaxel resistance. As in Figure 3, the anti-Plk2 antibody 
used for western blotting detects a doublet, the upper band of which is Plk2 (arrowed). 
PCNA is shown as a loading control.  
 
Figure 6 
Reversal of paclitaxel resistance by growth in the absence of drug.  A: Flow cytometry 
analysis of A2780 parent cells and paclitaxel-resistant A2780TaxR354 and A2780TaxR615 
sub-lines. Parent A2780 cells and derivative cell lines allowed a six week period of growth 
in drug-free medium (-) were exposed to paclitaxel then subjected to flow cytometry. B: 
Expression of Plk2 mRNA in A2780 cell lines grown with (dark grey boxes) or without 
maintenance paclitaxel (light grey boxes). Expression is relative to parent A2780 cells. C: 
MSP analysis of the Plk2 CpG island in A2780 cell lines grown with (+) or without (-) 
maintenance paclitaxel. Controls are:  CU (control unmethylated DNA) and CM (control 
methylated DNA). MSP reactions for unmethylated (U) and methylated (M) alleles are 
shown.  
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Figure 7 
Expression of Plk2 modulates response to paclitaxel and carboplatin . A: Expression of Plk2 
mRNA in A2780 parent cells was “knocked-down” using inhibitory RNA (RNAi) and stable 
Knock-Down confirmed by RT-PCR. Expression of Plk2 was then restored to the knocked-
down cells by ectopic expression (Knock-In: “KD+ KI”). B: Flow cytometric analysis of the 
effect of paclitaxel in A2780 cells. Cells were treated with paclitaxel and subjected to flow 
cytometry 48 hours later as indicated. C: Knock-in of Plk2 in A2780 cells with acquired 
paclitaxel resistance. A2780TaxR354 cells were transfected with a plasmid expressing Plk2 
(A2780TaxR354 KI), then challenged with paclitaxel. D: Western blot analysis of expression 
of Plk2 in SKOV-3 cells following knock-down. E: Parent SKOV-3 cells were treated with 
subcytotoxic doses of paclitaxel or carboplatin following Plk2 knock-down or treatment 
with irrelevant SiRNA (control). Cells were harvested 48 hours after addition of cytotoxic 
agent. Similar results were obtained after 72 hours (n = 3).  
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